This information is intended for healthcare professionals only. Please confirm that you are a healthcare professional.
If you are not a healthcare professional, please click here to go to the home page
Note: OncoSil™ is currently approved in the European Union, the United Kingdom, Hong Kong, Singapore, Malaysia and New Zealand.
OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes for people living with cancer by utilising the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in combination with chemotherapy.
OncoSil™ is our brachytherapy device. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs1.
We believe in our technology and its ability to have a truly positive impact in Oncology.
Reference: 1. Skowronek J. J Contemp Brachytherapy 2017; 9: 581-589.